bioTheranostics’ New Biot3 Metastatic Cancer Solution Provides Comprehensive Genomic Testing With Integration Of Next Generation Sequencing
2/3/2014 12:32:39 PM
SAN DIEGO--(BUSINESS WIRE)--bioTheranostics, Inc., today introduced the bioT3 Metastatic Cancer Solution, a suite of genomic-based tests that provide personalized diagnostic information and therapeutic guidance for metastatic cancer patients across the continuum of care.
Help employers find you! Check out all the jobs and post your resume.
comments powered by